Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01995058 · ClinicalTrials.gov registry record · Phase 2
Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC
A Phase 2 study, sponsored by Exelixis.
- Terminated
- Registry status
- Phase 2
- Development phase
- 54
- Enrollment target
NCT01995058 is a Phase 2 study that was terminated before completion, run by Exelixis. The registered enrollment target is 54 participants.
The verdict
NCT01995058, a Phase 2 study, was terminated before completion, sponsored by Exelixis.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 54 participants
- Enrollment target
Study Summary
This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
Interventions
- DRUG prednisone
- DRUG cabozantinib
- DRUG abiraterone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2014-02 |
| Est. Completion | 2014-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01995058
The ClinicalTrials.gov registry entry for NCT01995058 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which prednisone is the first listed.
NCT01995058 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01995058 about?
NCT01995058 is a clinical study titled "Combo of Cabozantinib With Abiraterone in Chemotherapy-Naïve Subjects With Bone-Metastatic CRPC". This study was conducted in subjects in chemotherapy-naïve subjects with bone-metastatic castration-resistant prostate cancer (CRPC).
What is the current status of trial NCT01995058?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 54 participants. The study started on 2014-02. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01995058?
The interventions under investigation include: prednisone (DRUG), cabozantinib (DRUG), abiraterone (DRUG).
Who is sponsoring clinical trial NCT01995058?
This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.